Fig. 5

CN133 enhanced the anticancer effects of PD-1 blockade in C56BL/6 J mice of RM1 subcutaneous tumors by inhibited PMN-MDSC infiltration and enhanced CD8 T cell infiltration in TME. A Tumor volume of RM1 prostate cancer subcutaneous tumors treated with placebo, CN133, anti-PD-1 (1 mg/kg), or CN133 (1 mg/kg) combined with anti-PD-1. B Survival percentage were assessed after treatment of placebo, CN133, anti-PD-1, or CN133 plus anti-PD-1 in C57BL/J6 models. C Bioluminescent images (BLI) showing the luciferase intensity of subcutaneous tumors after treatments of placebo, CN133, anti-PD-1, or CN133 plus anti-PD-1. D In situ analyses of PMN-MDSC population of tumor by immunofluorescence staining in the TME of placebo, CN133, anti-PD-1, or CN133 plus PD-1 treatment C57BL/J6 mice; scale bar, 50 μm. E Immunofluorescent images showed the infiltration of CD3 + CD8 + T cells on C57BL/J6 subcutaneous PCa tumor tissues; scale bar, 50 μm. F, G Flow cytometric analyses showing percentages numbers of the PMN-MDSCs (F) and CD4 and CD8 T cells (G) in the spleens of placebo, CN133, anti-PD-1, or CN133 plus anti-PD-1 treatment of C57BL/J6 PCa mice